Free fatty acids are associated with metabolic syndrome and insulin resistance but not inflammation in systemic lupus erythematosus

Abstract

Free fatty acids (FFAs) are implicated in the pathogenesis of insulin resistance and atherosclerosis. Inflammatory cytokines promote lipolysis and increase FFAs, a cause of endothelial dysfunction and increased atherosclerosis risk. We hypothesized that increased inflammation is associated with increased FFAs, resulting in insulin resistance and atherosclerosis in patients with systemic lupus erythematosus (SLE). We measured clinical variables, serum FFAs, homeostasis model assessment for insulin resistance (HOMA), inflammatory cytokines, markers of endothelial activation, cholesterol concentrations and coronary artery calcium in 156 patients with SLE and 90 controls. We compared FFAs in patients with SLE and controls using Wilcoxon rank sum tests and further tested for the independent association between FFAs and disease status with adjustment for age, race and sex using multivariable regression models. We assessed the relationship between FFAs and continuous variables of interest using Spearman correlation and multivariable regression analysis. Levels of FFAs were higher in patients with SLE than controls (0.55 mmol/l (0.37–0.71) vs 0.44 mmol/l (0.32–0.60), P = 0.02). Levels of FFAs remained significantly higher among patients with SLE after adjustment for age, race and sex (P = 0.03) but not after further adjustment for body mass index (P = 0.13). FFA levels did not differ according to the usage of current immunosuppressive medications in univariate and adjusted analysis (all P > 0.05). Among patients with SLE, concentrations of FFAs were higher among those with metabolic syndrome compared to those without (0.66 mmol/l (0.46–0.81) vs 0.52 mmol/l (0.35–0.66), P < 0.001). FFAs were positively correlated with insulin resistance (HOMA) (rho = 0.23, P = 0.004, P adjusted = 0.006) and triglyceride levels (rho = 0.22, P = 0.01, P adjusted = 0.004). FFAs were not associated with inflammatory cytokines (IL-6, TNF-α) (all P > 0.05) but were positively associated with levels of E-selectin (rho = 0.33, P = < 0.001, P adjusted = 0.001) and ICAM-1 (rho = 0.35, P < 0.001, P adjusted = 0.001). FFAs were correlated with coronary artery calcium score (rho = 0.20, P = 0.01) but this was attenuated after adjustment for age, race and sex (P = 0.33). From our study we concluded that FFAs are elevated in patients with SLE, particularly those with metabolic syndrome. FFAs in patients with SLE are not associated with markers of generalized inflammation but are associated with insulin resistance and markers of endothelial activation

Keywords

Cardiovascular disease systemic lupus erythematosus free fatty acids metabolic syndrome endothelial activation insulin resistance

Get full access to this article

View all access options for this article.

References

Asanuma

Oeser

Shintani

. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. New Engl J Med 2003; 349: 2407–2415.

Roman

Shanker

Davis

. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. New Engl J Med 2003; 349: 2399–2406.

Esdaile

Abrahamowicz

Grodzicky

. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2331–2337.

Chung

Oeser

Avalos

Raggi

Stein

. Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus. Lupus 2006; 15: 562–569.

Chung

Avalos

Oeser

. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis 2007; 66: 208–214.

Hunt

Resendez

Williams

Haffner

Stern

. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004; 110: 1251–1257.

Boden

. Obesity and free fatty acids. Endocrin Metab Clin 2008; 37: 635–46, viii–ix.

Boden

. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997; 46: 3–10.

Langin

Holm

Lafontan

. Adipocyte hormone-sensitive lipase: a major regulator of lipid metabolism. P Nutr Soc 1996; 55: 93–109.

10.

Boden

Chen

. Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes. J Clin Invest 1995; 96: 1261–1268.

11.

Dresner

Laurent

Marcucci

. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 1999; 103: 253–259.

12.

Jensen

Haymond

Rizza

Cryer

Miles

. Influence of body fat distribution on free fatty acid metabolism in obesity. J Clin Invest 1989; 83: 1168–1173.

13.

Green

Dobias

Walters

Brasier

. Tumor necrosis factor increases the rate of lipolysis in primary cultures of adipocytes without altering levels of hormone-sensitive lipase. Endocrinology 1994; 134: 2581–2588.

14.

Souza

Yamamoto

Franciosa

Lien

Greenberg

. BRL 49 653 blocks the lipolytic actions of tumor necrosis factor-alpha: a potential new insulin-sensitizing mechanism for thiazolidinediones. Diabetes 1998; 47: 691–695.

15.

Boden

She

Mozzoli

. Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver. Diabetes 2005; 54: 3458–3465.

16.

Tripathy

Mohanty

Dhindsa

. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 2003; 52: 2882–2887.

17.

Mathew

Tay

Cusi

. Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects. Cardiovasc Diabetol 2010; 9: 9–9.

18.

Inoguchi

Umeda

. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C–dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000; 49: 1939–1945.

19.

Chinen

Shimabukuro

Yamakawa

. Vascular lipotoxicity: endothelial dysfunction via fatty-acid-induced reactive oxygen species overproduction in obese Zucker diabetic fatty rats. Endocrinology 2007; 148: 160–165.

20.

Schachinger

Britten

Zeiher

. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899–1906.

21.

Asanuma

Chung

Oeser

. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheum 2006; 33: 539–545.

22.

Rho

Chung

Oeser

. Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus. J Rheum 2008; 35: 1789–1794.

23.

Tan

Cohen

Fries

. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277.

24.

Bombardier

Gladman

Urowitz

Caron

Chang

. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630–640.

25.

Gladman

Ginzler

Goldsmith

. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363–369.

26.

Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143–3421.

27.

Matthews

Hosker

Rudenski

Naylor

Treacher

Turner

. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.

28.

Reilly

Wolfe

Rhodes

Girman

Mehta

Rader

. Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation 2004; 110: 803–809.

29.

Agatston

Janowitz

Hildner

Zusmer

Viamonte

Jr, Detrano

. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15: 827–832.

30.

Kawakami

Murase

Ogawa

. Human recombinant TNF suppresses lipoprotein lipase activity and stimulates lipolysis in 3T3-L1 cells. J Biochem 1987; 101: 331–338.

31.

Mattacks

Pond

. Interactions of noradrenalin and tumour necrosis factor alpha, interleukin 4 and interleukin 6 in the control of lipolysis from adipocytes around lymph nodes. Cytokine 1999; 11: 334–346.

32.

Van der Poll

Romijn

Wiersinga

Sauerwein

. Tumor necrosis factor: a putative mediator of the sick euthyroid syndrome in man. J Clin Endocr Metab 1990; 71: 1567–1572.

33.

van Hall

Steensberg

Sacchetti

. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocr Metab 2003; 88: 3005–3010.

34.

Gomez

Jequier

Chabot

Buber

Felber

. Carbohydrate and lipid oxidation in normal human subjects: its influence on glucose tolerance and insulin response to glucose. Metabolism 1972; 21: 381–391.

35.

Santomauro

Boden

Silva

. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes 1999; 48: 1836–1841.

36.

Ormseth

Swift

Fazio

. Free fatty acids are associated with insulin resistance but not coronary artery atherosclerosis in rheumatoid arthritis. Atherosclerosis 2011; 219: 869–874.

37.

Chung

Oeser

Solus

. Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum 2008; 58: 2105–2112.

38.

Taniguchi

Nakai

Fukushima

. Ultrasonographically assessed carotid atherosclerosis in Japanese type 2 diabetic patients: Role of nonesterified fatty acids. Metabolism 2002; 51: 539–543.

39.

Armstrong

Hiremagalur

Haluska

. Free fatty acids are associated with obesity, insulin resistance, and atherosclerosis in renal transplant recipients. Transplantation 2005; 80: 937–944.

40.

Steinberg

Baron

. Vascular function, insulin resistance and fatty acids. Diabetologia 2002; 45: 623–634.

41.

Rubio-Guerra

Vargas-Robles

Serrano

Vargas-Ayala

Rodriguez-Lopez

Escalante-Acosta

. Correlation between the levels of circulating adhesion molecules and atherosclerosis in hypertensive type-2 diabetic patients. Clin Exp Hypertens 2010; 32: 308–310.

42.

Krieglstein

Granger

. Adhesion molecules and their role in vascular disease. Am J Hypertens 2001; 14: 44S–54S.

43.

Reynolds

Buyon

Kim

. Association of plasma soluble E-selectin and adiponectin with carotid plaque in patients with systemic lupus erythematosus. Atherosclerosis 2010; 210: 569–574.